Amneal Pharmaceuticals, Inc. announced the completion of its acquisition of Kashiv BioSciences, LLC, creating a fully integrated global biosimilars leader with end-to-end capabilities across research, development, manufacturing and commercialization. The combination establishes one of the industry’s few fully integrated biosimilars platforms.
“The completion of this acquisition marks a pivotal step in Amneal’s strategy to become America’s #1 affordable medicines company,” said Chirag Patel, co-founder and co-chief executive officer. “With this acquisition, we have created an integrated biosimilars business that can launch multiple biosimilars each year and extends our growth profile into the next decade.”
“We are pleased to welcome the Kashiv team to Amneal and thank our shareholders and other stakeholders for their strong support,” said Chintu Patel, co-founder and co-chief executive officer. “This acquisition helps to position Amneal to capitalize on an unprecedented wave of biologic loss of exclusivity. Together, we will pursue this significant opportunity and work to expand patient access to high-quality, affordable biologic medicines.”
The acquisition combines Kashiv’s biologics research, development and manufacturing capabilities with Amneal’s commercial scale, establishing biosimilars as a major long-term growth pillar within the company’s affordable medicines business.
The transaction provides Amneal access to the global biosimilars market with more than $300 billion projected global biologics loss-of-exclusivity over the next decade. The combined portfolio is expected to support a consistent cadence of biosimilar launches for years to come.
